
| Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy #MMPMID32745524Chrousos GP; Meduri GUClin Immunol 2020[Oct]; 219 (?): 108550 PMID32745524show ga
?|Anti-Inflammatory Agents/*therapeutic use[MESH]|Betacoronavirus/drug effects/immunology/pathogenicity[MESH]|Biomarkers/blood[MESH]|COVID-19[MESH]|Coronavirus Infections/*drug therapy/immunology/metabolism/virology[MESH]|Cytokine Release Syndrome/*drug therapy/immunology/metabolism/virology[MESH]|Cytokines/antagonists & inhibitors/genetics/immunology[MESH]|Drug Administration Schedule[MESH]|Gene Expression Regulation[MESH]|Glucocorticoids/*therapeutic use[MESH]|Homeostasis/*drug effects/immunology[MESH]|Humans[MESH]|Hydrocortisone/blood[MESH]|Immunity, Innate/drug effects[MESH]|Inflammation/prevention & control[MESH]|NF-kappa B/genetics/immunology[MESH]|Pandemics[MESH]|Pneumonia, Viral/*drug therapy/immunology/metabolism/virology[MESH]|SARS-CoV-2[MESH]|Stress, Physiological[MESH]|Treatment Outcome[MESH]
  
DeepDyve Pubget Overpricing | 
|